US EditionPublished • loading... • Updated
MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
MediLink granted Roche exclusive rights to develop and commercialize YL201 globally except China, with $570 million upfront and milestone payments to accelerate global approvals.
- On Jan. 8, 2026 in Suzhou, MediLink Therapeutics announced it granted Roche an exclusive license to develop, manufacture and commercialize YL201 worldwide excluding mainland China, Hong Kong SAR and Macau.
- Building on a January 2024 tie-up, the companies said the agreement leverages complementary strengths to speed YL201 toward global regulatory approvals and deepens joint development ties for the YL211 program.
- Financial terms include US$ 570 million upfront and near-term payments plus milestones and royalties; YL201 earned FDA Breakthrough Therapy designation in June 2025 and Orphan Drug designations for SCLC, NPC and ESCC.
- YL201 is currently being studied in multinational trials for multiple advanced solid tumors, with preliminary data showing promising response rates and survival benefits in second-line small cell lung cancer patients.
- MediLink Therapeutics, with R&D subsidiaries in Shanghai, Boston and Singapore, leverages its TMALIN platform supporting three clinical-stage ADC candidates to support YL201's global development.
Insights by Ground AI
31 Articles
31 Articles
The Berkshire Eagle+29 Reposted by 29 other sources
MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- MediLink Therapeutics ("MediLink") today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational…
Roche returns to Chinese biotech MediLink for another ADC pact
Roche has signed another licensing deal with its China-based partner MediLink, this time focused on an antibody-drug conjugate for solid tumors that targets B7-H3. The Swiss drugmaker will obtain exclusive rights to MediLink’s drug, called ...
Coverage Details
Total News Sources31
Leaning Left4Leaning Right3Center6Last UpdatedBias Distribution46% Center
Bias Distribution
- 46% of the sources are Center
46% Center
L 31%
C 46%
R 23%
Factuality
To view factuality data please Upgrade to Premium
